Overview

Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis

Status:
Completed
Trial end date:
2019-10-04
Target enrollment:
Participant gender:
Summary
Phase 3, multi-center, randomized, masked, controlled study to evaluate the safety and efficacy of an injectable fluocinolone acetonide intravitreal (FAI) insert for the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye. Patients will be randomized to receive either a sham injection or the FAI insert and will be observed for three years following treatment.
Phase:
Phase 3
Details
Lead Sponsor:
EyePoint Pharmaceuticals, Inc.
pSivida Corp.
Treatments:
Fluocinolone Acetonide